Company Focus
Chugai
Latest Chugai News
Pharmaceutical
Japan’s Chugai Pharmaceutical revealed that it received regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) for the additional indication of its anti-cancer agent/ALK inhibitor Alecensa (alectinib) for advanced or recurrent ALK fusion gene-positive solid tumors, including pediatric patients. 21 May 2026
Related News
Insights
Company Spotlight
A Somerset, New Jersey-based cell therapy biotechnology company that generated $597 million in Carvykti net trade sales in Q1 2026 and sent shares up 42% in June 2026 on striking Phase I in vivo CAR-T lymphoma data.
Latest News & Features of interest to Chugai
Biotechnology
US clinical-stage biotech Kairos Pharma, which is focused on innovative cancer therapeutics, has provided a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from chief executive Dr John Yu. The firm’s shares rose 4.8% to $0.48 on the announcement. 5 June 2026
Biotechnology
US biotech Stipple Bio has signed a multi-target licensing agreement with Swiss life sciences supplier Lonza to support development of next-generation antibody-drug conjugates (ADCs), including its lead oncology candidate STP-100. 5 June 2026
Biotechnology
Parabilis Medicines announced today that it plans to raise up to $475 million through a US initial public offering. The biopharmaceutical company filed to offer 25 million shares priced between $17 and $19 each. 5 June 2026
Pharmaceutical
The 2026 American Society of Clinical Oncology (ASCO) annual meeting delivered several potentially practice-changing datasets across solid tumors and hematologic malignancies, while underlining the growing influence of Chinese biotech innovation, antibody-drug conjugates and next-generation targeted therapies. 4 June 2026
Biotechnology
CytomX Therapeutics announced an expansion of its collaboration and licensing agreement with Regeneron Pharmaceuticals to create conditionally-activated bispecific cancer therapies utilizing CytomX’s Probody therapeutic platform and Regeneron’s Veloci-Bi bispecific antibody development platform. 4 June 2026
Biotechnology
Shares in Switzerland-based ADC Therapeutics fell sharply in pre-market trading on Thursday after investors focused on safety findings and the lack of a clear overall survival advantage in the Phase III LOTIS-5 trial of Zynlonta (loncastuximab tesirine-lpyl) plus rituximab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL). 4 June 2026
Pharmaceutical
Spanish biotech Ona Therapeutics has raised $87 million in an oversubscribed series B round, giving the Barcelona company the cash to move its lead antibody-drug conjugate, ONA-255, into human studies. 4 June 2026
Biotechnology
US biotech Iovance Biotherapeutics, which is developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Therapeutic Goods Administration (TGA) of Australia granted approval with conditions of Amtagvi (lifileucel), a tumor-derived autologous T cell immunotherapy, for previously treated advanced (metastatic or unresectable) melanoma. 4 June 2026
Biotechnology
Chinese biopharma company Everest Medicines announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia. 3 June 2026
Biotechnology
US biotech company Celcuity reported detailed Phase III data for its investigational PI3K/AKT/mTOR inhibitor gedatolisib at the American Society of Clinical Oncology (ASCO) Annual Meeting, showing a significant progression-free survival (PFS) benefit in hormone receptor-positive, HER2-negative, PIK3CA-mutant advanced breast cancer. 3 June 2026
Latest In Brief for Chugai
Biotechnology
Shares of US cancer drug Revolution Medicines, with a market capitalization of more than $20 billion, rose nearly 29% following reports of a buyout from US pharma giant Merck & Co. 10 January 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze